Dr WANG Ning, Michael ( 王 寧 )



Similar documents
The Need for a PARP in vivo Pharmacodynamic Assay

Nian Gong, PhD. Department of Anesthesiology & Perioperative Care

Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine

How To Understand The Effects Of A Drug On Your Health

SINPE trial, Ann Surg Overall morbidity. Minor Major. Infectious Non infectious. Post-hoc analysis WL < %5 (n=379) WL between 5-10% (n=49)

SU Qiang Professor

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

New Data Supporting Modified RECIST (mrecist) for Hepatocellular Carcinoma. Running Title: Modified RECIST (mrecist) for Hepatocellular Carcinoma

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points

American Cancer Society Extramural Grants

M The Nucleus M The Cytoskeleton M Cell Structure and Dynamics

Course Curriculum for Master Degree in Clinical Pharmacy

Biochemistry Major Talk Welcome!!!!!!!!!!!!!!

Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD

Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases

Ph.D Programs at Near East University Faculty of Pharmacy

Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science

Pharmacology skills for drug discovery. Why is pharmacology important?

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

The role, responsibilities and status of the clinical medical physicist in AFOMP

How To Teach Bioengineering In Hong Kong

Bachelor of Science in Applied Bioengineering

MOLECULAR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr

M. Ugolini 1,2, G. Babini 1,2, G. Baiocco 1,2, D. Cappelletti 1,2, L. Mariotti 1,2, J. Morini 1,2,3 and A. Ottolenghi 1,2

HEALTH SCIENCES RESEARCH GROUPS AT THE UNIVERSITY OF ALICANTE. Field. Translational Research. Mortality Analysis. Public Health.

College of Pharmacy & Pharmaceutical Sciences Graduate Catalog

Overview of the Research Programs of School of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University

REGULATIONS FOR THE DEGREE OF BACHELOR OF PHARMACY IN CHINESE MEDICINE [PART-TIME] (BPharm[ChinMed])

FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN

A leader in the development and application of information technology to prevent and treat disease.

Anticancer Effects of and Direction of Research on Hippophae

Report from the visiting commitee

CURRICULUM VITAE. NAME: Huang,Po-Hao OFFICE ADDRESS: EDUCATION: EMPLOYMENT RECORD: PROFFESIONAL AFFILIATIONS: 黃 柏 豪

How To Use Berberine

Medical & Health Sciences

CytoSelect 48-Well Cell Adhesion Assay (ECM Array, Colorimetric Format)

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

The Postgraduate Course Toxicology Vienna

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

BIOSCIENCES COURSE TITLE AWARD

Survey on the Mortality from Malignant Tumors of Female Asbestos Spinning Workers

Masters Learning mode (Форма обучения)

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

Detailed Course Descriptions for the Human Nutrition Program

Bachelor of Science in Biochemistry and Molecular Biology

Therapeutic Goods Administration Orphan Drugs Program: Discussion paper

PharmD Postdoctoral Fellowship Program

EDUCATION University of Illinois at Chicago Postdoc (Bioengineering, Modeling of biological networks) 2012

Cytotoxic and Biotherapies Credentialing Programme Module 2

Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015

CONNECTED TRANSACTION FORWARD SHARE PURCHASE

SACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS

The Victory Over Cancer Is At Hand

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

Master of Science in Biochemistry (Molecular Medicine Option).

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY

School of Nursing Doctor of Philosophy/Master of Philosophy Research Postgraduate Studies

MATHEMATICAL MODELS OF TUMOR GROWTH INHIBITION IN XENOGRAFT MICE AFTER ADMINISTRATION OF ANTICANCER AGENTS GIVEN IN COMBINATION

ANNOUNCEMENT ON THE APPROVALS CONCERNING THE QUALIFICATION OF DIRECTORS

Hepatitis C Glossary of Terms

Accounting Information and Stock Price Reaction of Listed Companies Empirical Evidence from 60 Listed Companies in Shanghai Stock Exchange

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Publikationsliste Claudia Götz

Curriculum Vitae Harvard Medical School/ Harvard School of Dental Medicine

STEM CELL FELLOWSHIP

Clinical Trials. In Singapore. Clinical Trials in Asia Pacifi c. Introduction. Healthcare Clusters.

Guidance for Industry Safety Testing of Drug Metabolites

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

a Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature

Elective Options for MS in Clinical and Translational Sciences Program

Diabetes and Drug Development

Have a Bright Idea? University of North Texas Master of Science in Environmental Science

Perspectives on the Future of Graduate Education in Medicinal Chemistry and Pharmacognosy 1

Doctor of Pharmacy Degree Requirements

Biochemistry. Entrance Requirements. Requirements for Honours Programs. 148 Bishop s University 2015/2016

Version Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

DMPK: Experimentation & Data

For additional information on the program, see the current university catalog.

Designing Visfatin inhibitors to limit its Insulin Mimcy and Type II Diabetes.

School Counseling: Current International Perspectives


S1 Text. Modeling deterministic single-cell microrna-p53-mdm2 network Figure 2 Figure 2

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Workshop on Internet and BigData Finance (WIBF)

Pharmacology (BCP) Pharmacology (BCP) Requirements for the Major in Pharmacology (BCP) PHARMACOLOGY (BCP) Spring Major in Pharmacology

Micro RNAs: potentielle Biomarker für das. Blutspenderscreening

LIST OF CONFERENCE PARTICIPANTS

Call 2014: High throughput screening of therapeutic molecules and rare diseases

TOP SPRING INTERNATIONAL HOLDINGS LIMITED

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Transcription:

Dr WANG Ning, Michael ( 王 寧 ) Research Assistant Professor School of Chinese Medicine, The University of Hong Kong CONTACT INFORMATION Address: School of Chinese Medicine, 10 Sassoon Road, Pokfulam, Hong Kong Tel: (852) 3917 6441 Fax: (852) 2872 5476 Email: ckwang@hku.hk ACADEMIC QUALIFICATIONS 09/2002-08/2006 Bachelor of Science in Biotechnology (Sun Yat-sen University, China) 09/2006-08/2008 Master of Science in Pharmaceutical Science (Sun Yat-sen University, China) 09/2008-06/2012 Doctor of Philosophy in Pharmacology (The University of Hong Kong, Hong Kong) WORK EXPERIENCE 08/2015 - Present Research Assistant Professor, School of Chinese Medicine, The University of Hong Kong 05/2014-07/2014 Visiting Research Fellow, School of Medicine, King s College London, UK 08/2012-07/2015 Post-Doctoral Fellow, School of Chinese Medicine, The University of Hong Kong RESEARCH INTERESTS 1. Quality control and standardisation of Chinese herbal Medicine; 2. Molecular pharmacology of Chinese herbal Medicine in treating metabolic disorders (obesity, hepatic diseases and diabetes mellitus, etc.) and cancers; 3. Chemical profile-biological response relationship of Chinese Medicine formulas; 4. Pharmacokinetics and herbal-drug interaction of Chinese herbal Medicine; 5. Translational study and drug discovery in natural products and Chinese Medicine formula PUBLICATIONS (in chronological order, Citation record from Google Scholar) [1] Wang X, Wang N, Cheung F, Lao L, Li C, Feng Y. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms. J Integr Med. 2015 13(3):142-164. [2] Wang L, Wang N, Tan H, Zhang Y, Feng Y. Protective Effect of a Chinese Medicine Formula He-Ying-Qing-Re Formula on Diabetic Retinopathy. J Ethnopharmacol. 2015 Apr

27. pii: S0378-8741(15)00297-4. doi: 10.1016/j.jep.2015.04.031. (IF:2.939) [3] Wang N, Feng Y, Tan HY, Cheung F, Hong M, Lao L, Nagamatsu T. Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma. J Ethnopharmacol. 2015 22;164:309-18. (IF:2.939) [4] Wang N, Feng Y. Elaborating the Role of Natural Products-Induced Autophagy in Cancer Treatment: Achievements and Artifacts in State-of-Art. Biomed Res Int. 201: 934207. (IF:2.706) [5] Wang X, Feng Y, Wang N, Cheung F, Tan HY, Zhong S, Li C, Kobayashi S. Chinese Medicines Induce Cell Death: The Molecular and Cellular Mechanisms for Cancer Therapy. Biomed Res Int. 2014:530342. (IF:2.706) [6] Wang N, Feng Y, Cheung F, Wang X, Zhang Z, Feng Y. A Chinese Medicine Formula Gegen Qinlian Decoction Suppresses Expansion of Human Renal Carcinoma With Inhibition of Matrix Metalloproteinase-2. Integr Cancer Ther. 2014 Sep 15. pii: 1534735414550036. [Epub ahead of print] (IF:2.014) [7] Wang N, Zhu M, Wang X, Tan HY, Tsao SW, Feng Y. Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta-Gene Regulatory Mechanism. 2014 1839:849-57. (IF:5.440) [8] Tian Y, Teng LR, Song JJ, Meng QF, Lu JH, Zhang WW, Wei K, Wang N, Wang D, Teng LS. Studies on the analgesic activities of Jia-Yuan-Qing pill and its safety evaluation in mice. Protoplasma. 2014 251:1245-53. (IF:3.171) [9] Xu B, Wang N, Pan W, Qiu J, Cao P, Zhu M, Feng Y, Liang G. Synthesis and anti-tumor activity evaluation of Matijin-Su derivatives. Bioorg Chem. 2014 56:34-40. (IF:2.141, co-first author) [10] Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y. MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. Mol Cancer. 2013 12:119. (IF:5.397, Citation:8) [11] Tan HY, Wang N, Tsao SW, Zhang Z, Feng Y. Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in Coptidis rhizome in hepatocellular carcinoma. Integr Cancer Ther. 2014 13:425-34. (IF:2.014) [12] Wang N, Feng Y, Zhu M, Siu FM, Ng KM, Che CM. A novel mechanism of XIAP degradation induced by timosaponin AIII in hepatocellular carcinoma. Biochim Biophys Acta-Molecular Cell Research. 2013 1833:2890-9. (IF:5.297, Citation:4) [13] Cheung F, Wang X, Wang N, Yuen MF, Ziea TC, Tong Y, Wong VT, Feng Y. Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2013:487919. (IF:2.175, Citation:3) [14] Wang N, Feng Y, Cheung F, Chow OY, Wang X, Su W, Tong Y. A comparative study on the hepatoprotective action of bear bile and Coptidis Rhizoma aqueous extract on experimental liver fibrosis in rats. BMC Complement Altern Med. 2012 12:239. (IF:1.877, Citation:6) [15] Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y. Up-regulation of TIMP-1 by genipin inhibits MMP-2 activities and suppresses the metastatic potential of human hepatocellular

carcinoma. PLoS One. 2012 7:e46318. (IF:3.534, Citation:16) [16] Wang XB, Feng Y, Wang N, Cheung F, Wong CW. Recent progress on anti-liver fibrosis candidates in patents of herbal medicinal products. Recent Patent Food Nutrition Agriculture. 2012 4:91-106.(Citation:10) [17] Cheung F, Feng Y, Wang N, Yuen MF, Tong Y, Wong VT. Effectiveness of Chinese herbal medicine in treating liver fibrosis: a systematic review and meta-analysis of randomized controlled trials. Chine Med. 2012 7:5. (IF:2.340, Citation:5) [18] Feng Y, Wang N, Ye X, Li H, Feng Y, Cheung F, Nagamatsu T. Hepatoprotective effect and its possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats. J Ethnopharmacol. 2012 138:683-90. (IF:2.939, Citation:52) [19] Wang N, Zhu M, Tsao SW, Tong Y, Feng Y. Tumor necrosis factor-a up-regulates the microrna-21 expression and promotes cell migration in human hepatocellular carcinoma cells MHCC97-L. Int J Cancer 2011 128, Suppl 1, 38. (IF:5.007, supplement issue) [20] Zhu M, Wang N, Tsao SW, Tong Y, Feng Y.3Alpha,7beta-dihydroxy-5 beta-cholan-24-oic acid N-(2-sulfoethyl)amide alters the micrornas expression and promotes cell migration of human hepatocellular carcinoma cells. Int J Cancer 2011 128, Suppl 1, 39. (IF:5.007, supplement issue) [21] Feng Y, Wang N, Zhu M, Feng Y, Li H, Tsao S. Recent progress on anticancer candidates in patents of herbal medicinal products. Recent Patents on Food, Nutrition & Agriculture 2011 3:30-48. (Citation:24) [22] Wang N, Pan W, Zhu M, Hao X, Zhang M, Liang G, Feng Y*. Fangchinoline induces autophagic cell death via p53/sestrin2/ampk signaling in human hepatocellular carcinoma cells. Br J Pharmacol, 2011, 164:731-742. (IF:4.990, Citation:27) [23] Zhu M, Wang N, Tsao SW, Yuen MF, Feng Y, Wan TS, Man K, Feng Y. Up-regulation of micrornas, mir21 and mir23a in human liver cancer cells treated with Coptidis rhizoma aqueous extract. Exp Ther Med. 2011 2: 27-32. (IF:0.941, Citation:17) [24] Wang N, Feng Y, Xie T, Su W, Zhu M, Chow OY, Zhang Y, Ng, KM, Leung CH, Tong Y. Chemical and biological analysis of active free and conjugated bile acids in animal bile using HPLC-ELSD and MTT methods. Exp Ther Med. 2011 2: 125-30 (IF:0.941, Citation:4) [25] Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem, 2010 111: 1426-36. (IF:3.368, Citation:77) [26] Wang N, Feng Y, Lau EP, Tsang C, Ching Y, Man K, Tong Y, Nagamatsu T, Su W, Tsao S. F-actinreorganization and inactivation of rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma cell migration. Integr Cancer Ther, 2010 9:354-64. (IF:2.014, Citation: 27) [27] Feng Y, Siu KY, Ye X, Wang N, Yuen MF, Leung CH, Tong Y, Kobayashi S. Hepatoprotective effects of berberine on carbon tetrachloride-induced acute hepatotoxicity in rats. Chin Med. 2010 18;5:33. (IF:2.340, Citation: 24) [28] Feng Y, Cheung KF, Wang N, Liu P, Nagamatsu T, Tong Y. Chinese medicines as a resource for liver fibrosis treatment. Chin Med. 2009 20;4:16. (IF:2.340, Citation: 23) [29] Wang N, Wang Y, Li P, Peng W, Xie T, Feng Y, Su W. The Bioavaliability of

Hepatoprotective Flavoniods in Hypericum Japonicum Extract. Journal of Bioanalysis & Biomedicine. 2009 1:33-8 (Citation:2) [30] Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol. 2009 126:5-17. (IF:2.939, Citation:216) [31] Guan S, Su W, Wang N, Li P, Wang Y. Effects of radix polygoni multiflori components on tyrosinase activity and melanogenesis. J Enzyme Inhib Med Chem 2008 23:252-5. (IF:2.383, Citation:2) [32] Guan S, Su W, Wang N, Li P, Wang Y. A potent tyrosinase activator from Radix Polygoni multiflori and its melanogenesis stimulatory effect in B16 melanoma cells. Phytother Res 2008 22:660-3. (IF:2.397, Citation:15) [33] Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use and animal protection. J Ethnobi and Ethnomed. 2009, 5:2 (1-9). (IF:1.978, Citation:39) [34] Wang N, Li P, Wang Y, Peng W, Wu Z, Tan S, Liang S, Shen X, Su W. Hepatoprotective effect of Hypericum japonicum extract and its fractions. J Ethnopharmacol, 2008 116:1-6. (IF:2.939, Citation: 40) CONFERENCE ABSTRACT [1] Wang N, Tan HY, Feng Y. Experimental evidence of the pharmacylogical activety of Huanglian-containing Chinese Medicine formula in treating cancer on ICICM 2015, August 2015, Hong Kong, China. [2] Wang N, Tan HY, Feng Y. Suppression of nascent protein synthesis by natural product berberine on 19th World Congress on Advances in Oncology & 17th International symposium on Molecular Medicine, October, 2014, Athens, Greece. [3] Wang N, Feng Y. The anti-metastatic effect of genipin, a natural product in Gardnia Kasminoides Ellis on hepatocellular carcinoma and its underlying mechanism. 11th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). August, 2013, Graz, Austria. [4] Wang N and Feng Y, Comparison on the therapeutic action of coptis and bear bile on experimental liver fibrosis, 4th World Congress on Bioavailability Summit, May 2013, Beijing, China. [5] Wang N and Feng Y, Differential inhibitory effect of berberine on human hepatocellular carcinoma, The 8th international postgraduate symposium on Chinese medicine. August 2012, Hong Kong, China. [6] Wang N and Feng Y, The anti-metastatic potential of Gegen Qinlian Decoction in human renal carcinoma and its underlying mechanism, 11th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). August 2012, Macau, China. [7] Wang N, Zhu M, Tsao SW, Tong Y, Feng Y. Tumor necrosis factor-a up-regulates the microrna-21 expression and promotes cell migration in human hepatocellular carcinoma cells MHCC97-L. 1st Excellence in Oncology, Novmember 2010, Athens Greece. [8] Wang N, Pan W, Zhu M, Zhang M, Hao X, Liang G, Feng Y, Fangchinoline is a potential anti-cancer drug by inducing autophagic cell death in heaptocellular carcinoma

cells, 10th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), August, 2011, Shanghai, China. [9] Wang N, Zhu M, Tong Y, Tsao SW, Feng Y. Type1 and type 2 cell deaths on anti-tumor effect of berberine in liver cancer cells. 9th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), August, 2010 Hong Kong, China [10] Wang N, Feng Y, Tang J, Tsao SW, Tong Y. The anti-tumor action of coptidis rhizome and its major compound berberine: ancient drug with novel use. 5th International Congress on Complementary and Alternative Medicine, May, 2010, Tromsø, Norway. BOOK CHAPTER 1. Feng Y, Chan H, Wang N, Zhu M, Cheung F, Hong M. MIR23A (microrna 23a) Atlas Genet Cytogenet Oncol Haematol. 2013;17(12):825-827. Electronic database by INIST-CNRS 2. Feng YG, Wang N, Chueng F, Zhu M, Li H, Feng Y. Molecular and Cellular Mechanism Studies on Anticancer Effects of Chinese Medicines. Chapter in Biomedical Engineering, Trends, Research and Technologies (pp332-362). ISBN 978-953-307-514-3. 2011, pp644. 3. Feng Y, Chen XM, Wang N and Shen JG. Current Progress on Medicinal Plants and their Biological Properties in Contemporary China (Around 20,000 words). Chapter in Recent Progress in Medicinal Plants Vol. 28: Ethnomedicine: Source & Mechanism-II. Studium Press LLC, USA. 2010, pp491-546. PATENTS 1. Pan W, Feng Y, Liu Y, Wang N, Huang L, Liang G, et al. Chinese Patent Application No. 20140403363.X filed 18 August 2014 2. Feng Y, Wang N. Chinese Patent Application No. 201010246367.3 filed 27 July 2010 Title: The New Use of Coptidis Rhizoma Total Alkaloids. Update: June 2016